Platinum-Sensitive Malignant Female Reproductive System Neoplasm

Platinum-Sensitive Malignant Female Reproductive System Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

26 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 15
Recruiting: 7
Ph III recruiting: 2
Growth YoY: —
Industry share: 33%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (4)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04034927	Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer	active not recruiting	Phase 2	61	National Cancer Institute (NCI)NIH	1	Aug 26, 2026	clinicaltrials
NCT04550494	Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations	active not recruiting	Phase 2	29	National Cancer Institute (NCI)NIH	1	Aug 19, 2026